Benralizumab as an Adjuvant Therapy for Recurrent Laryngeal Papillomatosis

Kayla J. Krause, David Goldrich, John Gniady

Research output: Contribution to journalArticlepeer-review


Recurrent respiratory (RRP) or laryngeal papillomatosis is the result of human papillomavirus-mediated benign tumor growth on the larynx and is challenging to manage. Benralizumab is a monoclonal antibody targeted against the alpha subunit of the IL-5 receptor on eosinophils. A 61-year-old male patient presented with refractory RRP following multiple surgical excisions. His disease course improved substantially when benralizumab was added to his asthma regimen. There is no clear mechanistic role suggested for benralizumab directly treating RRP. This case may represent a novel application of benralizumab as an adjuvant treatment for patients with RRP and comorbid asthma. Laryngoscope, 133:863–865, 2023.

Original languageEnglish (US)
Pages (from-to)863-865
Number of pages3
Issue number4
StatePublished - Apr 2023

All Science Journal Classification (ASJC) codes

  • Otorhinolaryngology


Dive into the research topics of 'Benralizumab as an Adjuvant Therapy for Recurrent Laryngeal Papillomatosis'. Together they form a unique fingerprint.

Cite this